LEISHDNAVAX

LEISHDNAVAX

at a glance

TARGET DISEASE

Cutaneous Leishmaniasis

TIMELINE

01 September 2017 to 31 March 2020

COORDINATOR

European Vaccine Initiative

FUNDER

GHIT Fund

FUNDING

3.1 Mio Euro

SUMMARY

Preclinical and preparation of early clinical testing of a new vaccine candidate against cutaneous leishmaniasis

The use of vaccines against human leishmaniasis has been a long-term aim, however, there is not yet a licensed vaccine for human use. Several vaccine have been proposed and are at different stages of development.
LEISHDNAVAX is a candidate pentavalent DNA vaccine coding for optimized and T cell epitope-enriched antigens of Leishmania. Previously, this DNA vaccine has been successfully tested in ex vivo human T cell stimulation studies for antigenicity and immunogenicity in cutaneous and visceral leishmaniasis, and in a mouse model for immunogenicity and effectiveness against visceral leishmaniasis.
The LEISHDNAVAX project seeks to establish a new vaccine principle for leishmaniasis with a special focus on the induction of cell-mediated immunity, including the potential of the LEISHDNAVAX vaccine candidate to protect against cutaneous leishmaniasis in a preclinical animal model. In addition, the project aims also at starting the preparation of a phase I clinical trial for the evaluation of the safety and immunogenicity of the vaccine candidate.

Prev_PKDL_logo.jpg

PARTNERS

Charité – Universitätsmedizin Berlin (Germany); European Vaccine Initiative (Germany); London School of Hygiene and Tropical Medicine (LSHTM) (UK); Mologen AG (Germany); University of Nagasaki (Japan).

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

© 2020 European Vaccine Initiative. Designed by European Vaccine Initiative